Metastasis-free Survival — A New End Point in Prostate Cancer Trials

Earlier this year, the Food and Drug Administration (FDA) approved apalutamide, an androgen receptor inhibitor, for treatment of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). The approval was based on SPARTAN, a randomized, placebo-controlled trial involving 1207…

Read the full post at The New England Journal of Medicine: Search Results in Health Policy and Reform
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive